FBIO: Citigroup Maintains Buy Rating, May 2026

Citigroup maintained its Buy rating on Fortress Biotech (FBIO) on May 18, 2026, signaling confidence in the biopharmaceutical company’s trajectory. The analyst firm kept its stance unchanged while the market digested recent developments. FBIO trades at $2.48, down from its $2.59 entry point when the rating was published. This analyst rating maintained reflects steady conviction in the company’s pipeline and commercial products despite near-term volatility.

Analyst Rating Maintained on FBIO

Citigroup’s decision to maintain its Buy rating on Fortress Biotech underscores analyst confidence in the company’s strategic direction. The rating maintained status means the firm sees no reason to shift its outlook despite market fluctuations. FBIO currently trades above its 50-day average of $2.61 and below its 200-day average of $2.93. The stock has recovered 2.9% today, gaining $0.07 per share. This analyst rating maintained reflects a balanced view of both opportunities and risks in the biotech sector.

Price Target Raised to $5 at Alliance Global

Alliance Global recently raised its price target on FBIO to $5 from $4.50, signaling optimism about the company’s near-term prospects. This price target increase reflects confidence in Fortress Biotech’s pipeline. The new $5 target implies 101% upside from current levels. This analyst rating maintained by Citigroup aligns with the broader bullish sentiment. The move suggests analysts see catalysts ahead that could drive shareholder value.

Financial Metrics and Valuation

Fortress Biotech trades at a compelling valuation with a P/E ratio of 0.62 and price-to-sales of 1.20. The company boasts a current ratio of 2.86, indicating strong liquidity to fund operations and R&D. Free cash flow yield stands at 1.95%, while ROE reaches 1.61%. Market cap sits at $79.9 million with 32.2 million shares outstanding. These metrics support the analyst rating maintained stance, showing FBIO has financial flexibility for its development programs.

Meyka AI Stock Grade and Outlook

Meyka AI rates FBIO with a grade of B+, reflecting solid fundamentals and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s net income grew 115% year-over-year, while EPS surged 97%. These grades are not guaranteed and we are not financial advisors. The analyst rating maintained by Citigroup aligns with Meyka’s constructive assessment of the biotech firm’s trajectory.

Final Thoughts

Citigroup’s maintained Buy rating on Fortress Biotech reflects steady analyst conviction in the company’s biopharmaceutical pipeline and commercial products. The recent price target increase to $5 from Alliance Global adds bullish momentum to the analyst rating maintained narrative. With strong liquidity, compelling valuation metrics, and a B+ Meyka grade, FBIO appears positioned for potential upside. Investors should monitor upcoming catalysts and earnings announcements scheduled for August 13, 2026.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.